Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
about
Recurrent prostate cancer genomic alterations predict response to brachytherapy treatmentPARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesisThe ETS family of oncogenic transcription factors in solid tumours.The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc.The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP InhibitionCancer subclonal genetic architecture as a key to personalized medicine.Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer cells.LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.PARP Inhibitors in Prostate Cancer.There and Back Again: The Middle Earth of DNA Repair.Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.
P2860
Q33852664-9A5F5678-D37F-4BEA-990F-F5E30F01E9F7Q34434937-8702E6CA-1E91-40B8-A456-D0313C05487EQ34555986-7BC9ABF9-4E53-408B-8ADE-2D2492972C70Q34558930-6F6674B6-6D0D-4576-AE00-B31C531C2B6CQ35930506-41DEF663-D6C0-42C3-9B7D-ADC50B762171Q37448116-AE12D264-9403-449F-B9C5-7E46B4459A36Q37727814-33AA3A49-5FB6-4A96-9FE1-4B9AD0D1B1E8Q38435441-CEA85FB8-9427-4373-94E3-19CF72135788Q38788554-8D5A2A93-337B-490C-A8D8-5DCF965F00AAQ38873431-D8664BB0-D4D7-4ECF-BC9C-C0B1D6EDCC86Q38898477-CE818D17-C37B-42E3-9B11-C976221A9200Q38930155-E8685C99-D9C6-47E6-AD06-2E70DFD084CDQ38988375-CDA11BC5-58A0-4B56-96B3-9C5AF5D82733Q39021756-BABB5EE5-29B1-4F0E-B05E-5447B25418C1Q39328164-CF3D3FBF-473D-4C15-8582-05196C421D6AQ41653516-401268F2-26A3-4C1B-B7F4-0454A6C2B7E1Q42083096-8606EF6C-3549-41FD-87A8-19DAF7C59E4CQ54474207-4E2006FD-AE9C-479A-BC06-337B95E2C9F4
P2860
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted radiosensitization of ...... ncer through PARP1 inhibition.
@en
Targeted radiosensitization of ...... ncer through PARP1 inhibition.
@nl
type
label
Targeted radiosensitization of ...... ncer through PARP1 inhibition.
@en
Targeted radiosensitization of ...... ncer through PARP1 inhibition.
@nl
prefLabel
Targeted radiosensitization of ...... ncer through PARP1 inhibition.
@en
Targeted radiosensitization of ...... ncer through PARP1 inhibition.
@nl
P2093
P2860
P356
P1433
P1476
Targeted radiosensitization of ...... ncer through PARP1 inhibition.
@en
P2093
Aaron Sabolch
Arul M Chinnaiyan
Felix Y Feng
J Chad Brenner
Kari Wilder-Romans
Theodore S Lawrence
Will Jackson
P2860
P304
P356
10.1593/NEO.131604
P577
2013-10-01T00:00:00Z